BioAtla (BCAB) Competitors $0.32 0.00 (-0.94%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. EPIX, UNCY, SGMT, ADAG, ADVM, IGMS, LXEO, CRBP, RANI, and TCRXShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include ESSA Pharma (EPIX), Unicycive Therapeutics (UNCY), Sagimet Biosciences (SGMT), Adagene (ADAG), Adverum Biotechnologies (ADVM), IGM Biosciences (IGMS), Lexeo Therapeutics (LXEO), Corbus Pharmaceuticals (CRBP), Rani Therapeutics (RANI), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. ESSA Pharma Unicycive Therapeutics Sagimet Biosciences Adagene Adverum Biotechnologies IGM Biosciences Lexeo Therapeutics Corbus Pharmaceuticals Rani Therapeutics TScan Therapeutics BioAtla (NASDAQ:BCAB) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment. Do institutionals & insiders have more ownership in BCAB or EPIX? 77.2% of BioAtla shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 11.5% of BioAtla shares are held by company insiders. Comparatively, 15.5% of ESSA Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor BCAB or EPIX? In the previous week, ESSA Pharma had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for ESSA Pharma and 0 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat ESSA Pharma's score of 0.93 indicating that BioAtla is being referred to more favorably in the media. Company Overall Sentiment BioAtla Very Positive ESSA Pharma Positive Do analysts prefer BCAB or EPIX? BioAtla currently has a consensus price target of $6.00, indicating a potential upside of 1,804.16%. ESSA Pharma has a consensus price target of $9.50, indicating a potential upside of 436.72%. Given BioAtla's stronger consensus rating and higher possible upside, research analysts plainly believe BioAtla is more favorable than ESSA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor BCAB or EPIX? ESSA Pharma received 324 more outperform votes than BioAtla when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 65.79% of users gave BioAtla an outperform vote. CompanyUnderperformOutperformBioAtlaOutperform Votes2565.79% Underperform Votes1334.21% ESSA PharmaOutperform Votes34975.87% Underperform Votes11124.13% Which has stronger earnings & valuation, BCAB or EPIX? ESSA Pharma has lower revenue, but higher earnings than BioAtla. ESSA Pharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M1.67-$123.46M-$1.44-0.22ESSA PharmaN/AN/A-$28.54M-$0.69-2.57 Which has more volatility & risk, BCAB or EPIX? BioAtla has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Is BCAB or EPIX more profitable? ESSA Pharma's return on equity of -24.61% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -187.30% -96.33% ESSA Pharma N/A -24.61%-23.87% SummaryESSA Pharma beats BioAtla on 9 of the 16 factors compared between the two stocks. Remove Ads Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.40M$2.85B$5.28B$7.36BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.1930.3821.6317.68Price / Sales1.67433.44371.0892.88Price / CashN/A168.6838.1534.64Price / Book0.213.416.373.94Net Income-$123.46M-$72.06M$3.20B$247.45M7 Day Performance3.55%0.83%1.79%0.48%1 Month Performance-8.35%-18.82%-9.41%-7.08%1 Year Performance-88.00%-30.46%9.61%-0.35% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.6507 of 5 stars$0.32-0.9%$6.00+1,804.2%-88.9%$18.40M$11M-0.1960Positive NewsGap DownEPIXESSA Pharma2.8132 of 5 stars$1.65+4.4%$9.50+475.8%-77.7%$73.24MN/A-2.3950Gap UpUNCYUnicycive Therapeutics2.8272 of 5 stars$0.61+11.4%$5.25+760.7%-47.9%$73.02M$680,000.00-0.639Gap UpSGMTSagimet Biosciences2.6849 of 5 stars$2.38+3.0%$22.40+841.2%-52.4%$73.01M$2M-1.668News CoverageADAGAdagene2.5132 of 5 stars$1.52-0.7%$8.00+426.3%-38.5%$71.61M$103,204.000.00260Short Interest ↑News CoveragePositive NewsADVMAdverum Biotechnologies3.9518 of 5 stars$3.43flat$27.83+711.5%-72.0%$71.35M$1M-0.57190Earnings ReportAnalyst ForecastNews CoverageIGMSIGM Biosciences4.0564 of 5 stars$1.19-0.8%$5.50+362.2%-86.5%$71.13M$2.68M-0.33190Positive NewsLXEOLexeo Therapeutics2.8302 of 5 stars$2.14+8.1%$22.20+937.4%-78.9%$71.04M$650,000.00-0.6858CRBPCorbus Pharmaceuticals3.4554 of 5 stars$5.80-4.0%$59.13+919.4%-86.0%$70.95MN/A-1.2440Positive NewsRANIRani Therapeutics2.3076 of 5 stars$1.23+3.4%$12.33+902.7%-79.0%$70.47M$1.03M-1.16110Gap DownTCRXTScan Therapeutics3.1343 of 5 stars$1.24flat$9.33+652.7%-83.1%$70.17M$2.82M-1.17100Gap Down Remove Ads Related Companies and Tools Related Companies EPIX Alternatives UNCY Alternatives SGMT Alternatives ADAG Alternatives ADVM Alternatives IGMS Alternatives LXEO Alternatives CRBP Alternatives RANI Alternatives TCRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
